The June 2026 Daubert Hearing: What It Means for Your Depo-Provera Lawsuit

If you have a Depo-Provera case pending — or are considering filing one — June 24 through 26, 2026 may be the most important three days in the history of this litigation. On those dates, a federal judge in Florida will evaluate whether the scientific testimony connecting Depo-Provera to meningioma brain tumors meets the legal standard for admissibility. The ruling will shape whether nearly 3,800 cases go to trial — or collapse before they get there.

Understanding the Daubert hearing does not require a law degree. This guide explains what it is, what will happen, why the December 2025 FDA label change makes Pfizer's challenge harder, and what the two possible outcomes mean for your case.

1. What Is a Daubert Hearing?

A Daubert hearing is a pretrial proceeding — named after the Supreme Court's 1993 decision in Daubert v. Merrell Dow Pharmaceuticals — in which a federal judge evaluates whether expert witness testimony meets the standards for admissibility under Rule 702 of the Federal Rules of Evidence.

The core question at a Daubert hearing is not whether the expert is right. It is whether the expert's testimony is based on sufficient facts and data, is the product of reliable methods, and has been reliably applied to the facts of the case. The judge acts as a "gatekeeper" — screening out testimony that does not meet scientific reliability standards before it ever reaches a jury.

In pharmaceutical mass tort MDLs, Daubert hearings on "general causation" — the question of whether a drug can cause a particular injury at all — are among the most consequential pretrial events. If the general causation experts are excluded, cases that depend on proving the drug caused the injury have no foundation.

2. What Will Happen June 24–26

Judge M. Casey Rodgers originally scheduled the Daubert hearings for late May 2026 but rescheduled them to June 24–26 due to a scheduling conflict. The three-day hearing is expected to proceed as follows:

1. 1

   Plaintiffs Present Their General Causation Experts

   Plaintiffs' attorneys will call their expert witnesses — epidemiologists, pharmacologists, neurologists, and other scientists — to explain the scientific basis for the conclusion that medroxyprogesterone acetate in Depo-Provera causes meningioma brain tumors. These experts will explain their methodology and the studies they relied upon, primarily the 2024 BMJ study and supporting epidemiological literature.

2. 2

   Pfizer Cross-Examines and Challenges

   Pfizer's attorneys will cross-examine plaintiffs' experts, challenging the strength of the epidemiological evidence, the experts' methodology, and whether the studies support the specific causal conclusions being offered. Pfizer will argue that the evidence is insufficient to establish general causation to the standard required by Daubert.

3. 3

   Pfizer Presents Its Defense Experts

   Pfizer will present its own experts — typically biostatisticians, epidemiologists, and pharmacologists — who will argue that the available science does not reliably establish that Depo-Provera causes meningiomas, or that the methodology used by plaintiffs' experts is flawed.

4. 4

   Judge Rodgers Issues a Written Ruling

   After the three-day hearing, Judge Rodgers will issue a written ruling — typically within weeks to months — determining which experts are admitted, partially admitted, or excluded. This ruling directly shapes the litigation path forward.

3. The Science Plaintiffs Will Present

Plaintiffs' experts will build their testimony on a growing body of peer-reviewed literature establishing the Depo-Provera meningioma link:

4. How Pfizer Will Challenge the Experts

Pfizer's Daubert challenge is expected to focus on several scientific and methodological arguments:

• Confounding variables. Pfizer will argue that the BMJ and other studies did not adequately control for other risk factors for meningioma (age, other hormonal exposures, genetic predispositions), making the causal inference unreliable.
• Dose-response relationship. Pfizer may argue the evidence does not adequately establish a clear dose-response curve — a hallmark of reliable causal inference in epidemiology — meaning the link appears inconsistent across different exposure levels.
• Selection bias. Pfizer may challenge the study populations, arguing that women who used Depo-Provera were more likely to present to healthcare providers for meningioma symptoms due to other reasons, inflating apparent incidence.
• "General causation" vs. "specific causation" distinction. Pfizer will argue that even if epidemiological associations exist at a population level, plaintiffs' experts cannot reliably testify that Depo-Provera caused any specific plaintiff's meningioma — blurring the line between general and specific causation challenges.

5. Why the December 2025 FDA Label Makes Pfizer's Job Harder

The December 2025 FDA label change fundamentally altered the Daubert calculus. Before December 2025, Pfizer could argue at Daubert that the scientific evidence was too weak and uncertain to meet the standard for reliable expert testimony. After December 2025, that argument must contend with the fact that the FDA's own scientific reviewers found the evidence sufficient to mandate a warning.

6. What Happens If Plaintiffs Win

If plaintiffs' experts survive the Daubert challenge — the outcome most legal analysts consider more likely given the FDA label change — the consequences cascade forward:

• December 2026 bellwether trials proceed with full expert testimony on causation
• Juries will hear that Depo-Provera causes meningiomas from credentialed expert witnesses
• Early bellwether verdicts — if large — create the settlement leverage that drives global MDL resolution
• Settlement negotiations accelerate: Pfizer, facing certain trial exposure with established causation, has strong incentive to begin discussing a global resolution
• New case filings accelerate as the legal viability of cases is confirmed

7. What Happens If Pfizer Wins

A complete exclusion of plaintiffs' general causation experts would be a serious blow — but not necessarily fatal to every case. If Judge Rodgers excludes key experts:

• Plaintiffs would likely seek interlocutory appeal or petition for permission to present new or revised expert submissions
• Cases may be stayed pending appeal, significantly delaying resolution
• However, the FDA's December 2025 label change would remain a powerful basis for appellate challenge to any exclusion ruling
• Partial exclusion (excluding some experts but not all) is more common than total exclusion in major pharmaceutical MDLs and would have a more nuanced effect on different case theories

Most legal analysts consider complete exclusion of plaintiffs' experts unlikely, given the strength of the BMJ study and the FDA's regulatory validation. Partial limitations on expert testimony are more probable.

8. The December 2026 Bellwether Trial

Assuming a favorable Daubert ruling, the first bellwether trial in MDL 3140 is scheduled for December 2026. Understanding bellwether trials is essential for families with pending cases:

9. What Families Should Do Now

The June 2026 Daubert hearing is a critical milestone for the litigation — but it should not change your calculus on when to consult an attorney about your own case. Here is why:

• Statute of limitations runs independently of the MDL. Your filing deadline is set by your state's law from the date you knew or should have known that your meningioma was connected to Depo-Provera. Waiting for the Daubert outcome could cause you to miss your filing window.
• The Daubert hearing does not affect whether your case is timely filed. It only affects what evidence goes to juries if your case reaches trial. File first, monitor the hearing outcome second.
• Individual settlements can occur at any time. Cases are not required to follow the MDL timeline. Many individual Depo-Provera cases have resolved or are in negotiation outside the formal MDL process.
• Free consultations are available. Attorneys handling these cases work on contingency — no upfront cost, no fee unless you recover. The only downside to consulting now is zero.

Frequently Asked Questions